Watchlist

Watchlist
Antares Pharma, Inc. (ATRS)
Antares Pharma, Inc. (ATRS)
Antares Pharma, Excellent Risk-Reward Profile
In the aftermath of Antares Pharma ( ATRS ) falling from $4.09 in mid-October to $1.58 by mid-November 2017 after it was learned that the FDA had issued a CRL for the company's TRT (testosterone replacement therapy) drug Xyosted, the stock has made a slow comeback beginning in December to a cu…
Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas
Welcome to the sixteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size …
Institutional Top Ideas Series: Opaleye Management
In the last entry of this series, we took a look at top ideas from Ra Capital Management, the best performing fund weve come across so far with heavily concentrated positions in their top ideas. Going forward, I hope to continue to delve into the portfolios of successful hedge funds …
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size …
Antares Pharma's (ATRS) CEO Robert Apple on Q1 2018 Results - Earnings Call Transcript
Antares Pharma, Inc. (NASDAQ:ATRS) Q1 2018 Earnings Conference Call May 8, 2018 8:30 AM ET Executives Jack Howarth - VP, Corporate Affairs Robert Apple - President and Chief Executive Officer Fred Powell - Executive Vice President and Chief Financial Officer Analysts Ore…
Antares Pharma Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Antares Pharma Inc. in conjunction with their 2018 Q1 earnings Read more …
Antares Pharma misses by $0.01, misses on revenue
Antares Pharma (NASDAQ: ATRS ): Q1 EPS of -$0.04 misses by $0.01 . More news on: Antares Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more …
Notable earnings before Tuesday's open
ACM , AES , AFI , ANIP , AQUA , ARMK , ATHM , ATRS , BLD , BMCH , BR , COHU , CORE , CRCM , CROX , CWH , DEA , DF , DISCA , DISH , DNR , DQ , EGN , ENDP , EPZM , ETM , EXPD , FI , FRTA , FSS , GCP , GTN , HAE , HAIN , HSIC , HUD , ICPT , IT , JD , JEC…
JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space
Welcome to the fourteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size…
JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond
Welcome to the thirteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size…
Antares Pharma, Inc. (ATRS)